English

Myovant Sciences Ltd.

EDGAR

MYOV Quarterly report (10-Q) · filed 2023-01-26

100 filing records in this dataset, filed from 2016-09-30 to 2023-01-26. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

100 million USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 100229000 USD Source

Operating margin

-51.78%

2023 Q3 · %

Exact inputs and evidence

Operating Income: -51895000 USD Source
Revenue: 100229000 USD Source

Operating cash flow

-103 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -169782000 USD Source
Operating Cash Flow: -66885000 USD Source

Free cash flow

-103 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -169782000 USD Source
Operating Cash Flow: -66885000 USD Source
Capital Expenditure: 614000 USD Source
Capital Expenditure: 386000 USD Source

Cash and cash equivalents: 251 million USD 2022-12-31 Source
Exact value

250590000 USD
Long-term debt including current maturities: 99.4 million USD 2019-03-31 Source
Exact value

99382000 USD
Shares outstanding: 97 million shares 2022-12-31 Source
Exact value

97028258 shares

Reported share-count change

3.60% · 3.37 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

93658206 shares · 2021-12-31· Source
97028258 shares · 2022-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

379 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Revenue: 230972000 USD · 2021-04-01 – 2022-03-31 Source
Revenue: 173405000 USD · 2021-04-01 – 2021-12-31 Source
Revenue: 116492000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 104824000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 100229000 USD · 2022-10-01 – 2022-12-31 Source

Net income

-184 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Net income: -205981000 USD · 2021-04-01 – 2022-03-31 Source
Net income: -146696000 USD · 2021-04-01 – 2021-12-31 Source
Net income: -21239000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -45619000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -57627000 USD · 2022-10-01 – 2022-12-31 Source

Operating cash flow

-270 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Operating cash flow: -268559000 USD · 2021-04-01 – 2022-03-31 Source
Operating cash flow: -168472000 USD · 2021-04-01 – 2021-12-31 Source
Operating cash flow: -76005000 USD · 2022-04-01 – 2022-06-30 Source
Operating cash flow: -66885000 USD · 2022-04-01 – 2022-09-30 Source
Operating cash flow: -76005000 USD · 2022-04-01 – 2022-06-30 Source
Operating cash flow: -169782000 USD · 2022-04-01 – 2022-12-31 Source
Operating cash flow: -66885000 USD · 2022-04-01 – 2022-09-30 Source

Capital expenditure

865 thousand USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Capital expenditure: 974000 USD · 2021-04-01 – 2022-03-31 Source
Capital expenditure: 723000 USD · 2021-04-01 – 2021-12-31 Source
Capital expenditure: 72000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 386000 USD · 2022-04-01 – 2022-09-30 Source
Capital expenditure: 72000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 614000 USD · 2022-04-01 – 2022-12-31 Source
Capital expenditure: 386000 USD · 2022-04-01 – 2022-09-30 Source

Free cash flow

-271 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Operating cash flow: -268559000 USD · 2021-04-01 – 2022-03-31 Source
Operating cash flow: -168472000 USD · 2021-04-01 – 2021-12-31 Source
Operating cash flow: -76005000 USD · 2022-04-01 – 2022-06-30 Source
Operating cash flow: -66885000 USD · 2022-04-01 – 2022-09-30 Source
Operating cash flow: -76005000 USD · 2022-04-01 – 2022-06-30 Source
Operating cash flow: -169782000 USD · 2022-04-01 – 2022-12-31 Source
Operating cash flow: -66885000 USD · 2022-04-01 – 2022-09-30 Source
Capital expenditure: 974000 USD · 2021-04-01 – 2022-03-31 Source
Capital expenditure: 723000 USD · 2021-04-01 – 2021-12-31 Source
Capital expenditure: 72000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 386000 USD · 2022-04-01 – 2022-09-30 Source
Capital expenditure: 72000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 614000 USD · 2022-04-01 – 2022-12-31 Source
Capital expenditure: 386000 USD · 2022-04-01 – 2022-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-01-26.

Financial data available through: 2022-03-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2022-03-31
Operating income: 6 of 11 periods available· newest 2022-03-31
Net income: 6 of 11 periods available· newest 2022-03-31
Operating cash flow: 6 of 11 periods available· newest 2022-03-31
Capital expenditure: 6 of 11 periods available· newest 2022-03-31
Total assets: 4 of 11 periods available· newest 2022-03-31
Total liabilities: 4 of 11 periods available· newest 2022-03-31
Current assets: 4 of 11 periods available· newest 2022-03-31
Current liabilities: 4 of 11 periods available· newest 2022-03-31
Cash and cash equivalents: 4 of 11 periods available· newest 2022-03-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2019-03-31
Shares outstanding: 4 of 11 periods available· newest 2022-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+289.4%

Prior period

USD 59.32 million

2020-04-01 – 2021-03-31
Current period

USD 230.97 million

2021-04-01 – 2022-03-31

Exact inputs and evidence

230972000 − 59317000 = 171655000 USD

59317000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
230972000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Year-over-year change in Revenue: 171655000 USD Concept: fundies:Revenue Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 230972000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1802927 Filing: 000167908222000071 Input fundies:Revenue: 59317000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1804263 Filing: 000167908222000071
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 49.15 million

Prior period

−USD 255.13 million

2020-04-01 – 2021-03-31
Current period

−USD 205.98 million

2021-04-01 – 2022-03-31

Exact inputs and evidence

-205981000 − -255134000 = 49153000 USD

-255134000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
-205981000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Year-over-year change in Net income: 49153000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -205981000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1459136 Filing: 000167908222000071 Input fundies:NetIncome: -255134000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1460313 Filing: 000167908222000071
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-172.5%

Prior period

USD 370.63 million

2020-04-01 – 2021-03-31
Current period

−USD 268.56 million

2021-04-01 – 2022-03-31

Exact inputs and evidence

-268559000 − 370628000 = -639187000 USD

370628000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
-268559000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Year-over-year change in Operating cash flow: -639187000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -268559000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1537588 Filing: 000167908222000071 Input fundies:OperatingCashFlow: 370628000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1538639 Filing: 000167908222000071
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-45.1%

Prior period

USD 1.77 million

2020-04-01 – 2021-03-31
Current period

USD 974,000

2021-04-01 – 2022-03-31

Exact inputs and evidence

974000 − 1773000 = -799000 USD

1773000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
974000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Year-over-year change in Capital expenditure: -799000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 974000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1551399 Filing: 000167908222000071 Input fundies:CapitalExpenditure: 1773000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1552357 Filing: 000167908222000071
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2021-04-01 – 2022-03-31

Revenue USD 230.97 million 100% of revenue
Operating costs Derived USD 418.32 million 181% of revenue
Operating income −USD 187.35 million −81% of revenue
Tax, interest and other Derived USD 18.64 million 8.1% of revenue
Net income −USD 205.98 million −89% of revenue

Cash

Operating cash flow −USD 268.56 million −116% of revenue
Capital expenditure USD 974,000 0.4% of revenue
Free cash flow Derived −USD 269.53 million −117% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 540% of revenue.
2022 Operating loss: operating costs were 181% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2018-04-01 – 2019-03-31	0	264826000 Derived	-264826000	8725000 Derived	-273551000	-225324000 Derived	Source 2018-04-01 – 2019-03-31: 0 USD Inspect Revenue Open source 2018-04-01 – 2019-03-31: -264826000 USD Inspect Operating Income Open source 2018-04-01 – 2019-03-31: -273551000 USD Inspect Net Income Open source 2018-04-01 – 2019-03-31: -224088000 USD Inspect Operating Cash Flow Open source 2018-04-01 – 2019-03-31: 1236000 USD Inspect Capital Expenditure Open source
2020 2019-04-01 – 2020-03-31	0	274887000 Derived	-274887000	14102000 Derived	-288989000	-222271000 Derived	Source 2019-04-01 – 2020-03-31: 0 USD Inspect Revenue Open source 2019-04-01 – 2020-03-31: -274887000 USD Inspect Operating Income Open source 2019-04-01 – 2020-03-31: -288989000 USD Inspect Net Income Open source 2019-04-01 – 2020-03-31: -221172000 USD Inspect Operating Cash Flow Open source 2019-04-01 – 2020-03-31: 1099000 USD Inspect Capital Expenditure Open source
2021 2020-04-01 – 2021-03-31	59317000	320101000 Derived	-260784000	-5650000 Derived	-255134000	368855000 Derived	Source 2020-04-01 – 2021-03-31: 59317000 USD Inspect Revenue Open source 2020-04-01 – 2021-03-31: -260784000 USD Inspect Operating Income Open source 2020-04-01 – 2021-03-31: -255134000 USD Inspect Net Income Open source 2020-04-01 – 2021-03-31: 370628000 USD Inspect Operating Cash Flow Open source 2020-04-01 – 2021-03-31: 1773000 USD Inspect Capital Expenditure Open source
2022 2021-04-01 – 2022-03-31	230972000	418318000 Derived	-187346000	18635000 Derived	-205981000	-269533000 Derived	Source 2021-04-01 – 2022-03-31: 230972000 USD Inspect Revenue Open source 2021-04-01 – 2022-03-31: -187346000 USD Inspect Operating Income Open source 2021-04-01 – 2022-03-31: -205981000 USD Inspect Net Income Open source 2021-04-01 – 2022-03-31: -268559000 USD Inspect Operating Cash Flow Open source 2021-04-01 – 2022-03-31: 974000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 231M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-03-31	Revenue	0	Revenue: 0 Open source
20202020-03-31	Revenue	0	Revenue: 0 Open source
20212021-03-31	Revenue	59317000	Revenue: 59317000 Open source
20222022-03-31	Revenue	230972000	Revenue: 230972000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

289.4% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-03-31	Year over year	No prior comparable period	Revenue: 0 Open source
20202020-03-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-03-31	Year over year	No prior comparable period	Revenue: 59317000 Open source Revenue: 0 Open source
20222022-03-31	Year over year	289.4%	Revenue: 230972000 Open source Revenue: 59317000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -81.1% 2022

Net margin -89.2% 2022

Free cash flow margin -116.7% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-03-31	Operating margin	Not reported	Operating Income: -264826000 Open source Revenue: 0 Open source
20202020-03-31	Operating margin	Not reported	Operating Income: -274887000 Open source Revenue: 0 Open source
20212021-03-31	Operating margin	-439.6%	Operating Income: -260784000 Open source Revenue: 59317000 Open source
20222022-03-31	Operating margin	-81.1%	Operating Income: -187346000 Open source Revenue: 230972000 Open source
20192019-03-31	Net margin	Not reported	Net Income: -273551000 Open source Revenue: 0 Open source
20202020-03-31	Net margin	Not reported	Net Income: -288989000 Open source Revenue: 0 Open source
20212021-03-31	Net margin	-430.1%	Net Income: -255134000 Open source Revenue: 59317000 Open source
20222022-03-31	Net margin	-89.2%	Net Income: -205981000 Open source Revenue: 230972000 Open source
20192019-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -224088000 Open source Capital Expenditure: 1236000 Open source
20202020-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -221172000 Open source Capital Expenditure: 1099000 Open source
20212021-03-31	Free cash flow margin	621.8%	Revenue: 59317000 Open source Operating Cash Flow: 370628000 Open source Capital Expenditure: 1773000 Open source
20222022-03-31	Free cash flow margin	-116.7%	Revenue: 230972000 Open source Operating Cash Flow: -268559000 Open source Capital Expenditure: 974000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -268.6M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-03-31	Operating cash flow	-224088000	Operating Cash Flow: -224088000 Open source
20202020-03-31	Operating cash flow	-221172000	Operating Cash Flow: -221172000 Open source
20212021-03-31	Operating cash flow	370628000	Operating Cash Flow: 370628000 Open source
20222022-03-31	Operating cash flow	-268559000	Operating Cash Flow: -268559000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -269.5M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-03-31	Free cash flow	-225324000	Operating Cash Flow: -224088000 Open source Capital Expenditure: 1236000 Open source
20202020-03-31	Free cash flow	-222271000	Operating Cash Flow: -221172000 Open source Capital Expenditure: 1099000 Open source
20212021-03-31	Free cash flow	368855000	Operating Cash Flow: 370628000 Open source Capital Expenditure: 1773000 Open source
20222022-03-31	Free cash flow	-269533000	Operating Cash Flow: -268559000 Open source Capital Expenditure: 974000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

191.1% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-03-31	Liabilities / assets	97.5%	Total Liabilities: 168643000 Open source Total Assets: 172977000 Open source
20202020-03-31	Liabilities / assets	202.2%	Total Liabilities: 214203000 Open source Total Assets: 105926000 Open source
20212021-03-31	Liabilities / assets	148.8%	Total Liabilities: 1078992000 Open source Total Assets: 725027000 Open source
20222022-03-31	Liabilities / assets	191.1%	Total Liabilities: 993488000 Open source Total Assets: 520011000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.95× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-03-31	Current assets / current liabilities	2.32×	Current Assets: 166792000 Open source Current Liabilities: 71973000 Open source
20202020-03-31	Current assets / current liabilities	1.02×	Current Assets: 87910000 Open source Current Liabilities: 85925000 Open source
20212021-03-31	Current assets / current liabilities	2.5×	Current Assets: 704645000 Open source Current Liabilities: 281340000 Open source
20222022-03-31	Current assets / current liabilities	1.95×	Current Assets: 488145000 Open source Current Liabilities: 250330000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2016-04-01 – 2017-03-31	−USD 83.44 million Exact value Exact value: -83440000 USD 2016-04-01 – 2017-03-31: -83440000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Myovant Sciences Ltd. · 2017-03-31 Myovant Sciences Ltd. (edgar:1679082) Net Income: -83440000 USD Concept: fundies:NetIncome Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ANetIncome&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:NetIncome: -83440000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myov-20190331.xml#258944 Filing: 000167908219000019 The citation records this snapshot. The page link may show a newer release later.	−USD 18.22 million Exact value Exact value: -18215000 USD 2016-04-01 – 2017-03-31: -18215000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Myovant Sciences Ltd. · 2017-03-31 Myovant Sciences Ltd. (edgar:1679082) Operating Cash Flow: -18215000 USD Concept: fundies:OperatingCashFlow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3AOperatingCashFlow&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18215000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myov-20190331.xml#258306 Filing: 000167908219000019 The citation records this snapshot. The page link may show a newer release later.	USD 967,000 Exact value Exact value: 967000 USD 2016-04-01 – 2017-03-31: 967000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Myovant Sciences Ltd. · 2017-03-31 Myovant Sciences Ltd. (edgar:1679082) Capital Expenditure: 967000 USD Concept: fundies:CapitalExpenditure Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ACapitalExpenditure&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 967000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myov-20190331.xml#274935 Filing: 000167908219000019 The citation records this snapshot. The page link may show a newer release later.	−USD 19.18 million Calculation and evidence -18215000 − 967000 USD Exact free cash flow: -19182000 USD 2016-04-01 – 2017-03-31: -18215000 USD · Inspect Operating Cash Flow · Source 2016-04-01 – 2017-03-31: 967000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Myovant Sciences Ltd. · 2017-03-31 Myovant Sciences Ltd. (edgar:1679082) Free cash flow: -19182000 USD Concept: free-cash-flow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18215000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myov-20190331.xml#258306 Filing: 000167908219000019 Input fundies:CapitalExpenditure: 967000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myov-20190331.xml#274935 Filing: 000167908219000019 The citation records this snapshot. The page link may show a newer release later.
2018 2017-04-01 – 2018-03-31	−USD 143.26 million Exact value Exact value: -143255000 USD 2017-04-01 – 2018-03-31: -143255000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Myovant Sciences Ltd. · 2018-03-31 Myovant Sciences Ltd. (edgar:1679082) Net Income: -143255000 USD Concept: fundies:NetIncome Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ANetIncome&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:NetIncome: -143255000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovant10kmarch312020.htm#1288405 Filing: 000167908220000026 The citation records this snapshot. The page link may show a newer release later.	−USD 117.26 million Exact value Exact value: -117255000 USD 2017-04-01 – 2018-03-31: -117255000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Myovant Sciences Ltd. · 2018-03-31 Myovant Sciences Ltd. (edgar:1679082) Operating Cash Flow: -117255000 USD Concept: fundies:OperatingCashFlow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3AOperatingCashFlow&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117255000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovant10kmarch312020.htm#1346045 Filing: 000167908220000026 The citation records this snapshot. The page link may show a newer release later.	USD 604,000 Exact value Exact value: 604000 USD 2017-04-01 – 2018-03-31: 604000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Myovant Sciences Ltd. · 2018-03-31 Myovant Sciences Ltd. (edgar:1679082) Capital Expenditure: 604000 USD Concept: fundies:CapitalExpenditure Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ACapitalExpenditure&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 604000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovant10kmarch312020.htm#1356210 Filing: 000167908220000026 The citation records this snapshot. The page link may show a newer release later.	−USD 117.86 million Calculation and evidence -117255000 − 604000 USD Exact free cash flow: -117859000 USD 2017-04-01 – 2018-03-31: -117255000 USD · Inspect Operating Cash Flow · Source 2017-04-01 – 2018-03-31: 604000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Myovant Sciences Ltd. · 2018-03-31 Myovant Sciences Ltd. (edgar:1679082) Free cash flow: -117859000 USD Concept: free-cash-flow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117255000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovant10kmarch312020.htm#1346045 Filing: 000167908220000026 Input fundies:CapitalExpenditure: 604000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovant10kmarch312020.htm#1356210 Filing: 000167908220000026 The citation records this snapshot. The page link may show a newer release later.
2019 2018-04-01 – 2019-03-31	−USD 273.55 million Exact value Exact value: -273551000 USD 2018-04-01 – 2019-03-31: -273551000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Myovant Sciences Ltd. · 2019-03-31 Myovant Sciences Ltd. (edgar:1679082) Net Income: -273551000 USD Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:NetIncome: -273551000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331.htm#1415776 Filing: 000167908221000017 The citation records this snapshot. The page link may show a newer release later.	−USD 224.09 million Exact value Exact value: -224088000 USD 2018-04-01 – 2019-03-31: -224088000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Myovant Sciences Ltd. · 2019-03-31 Myovant Sciences Ltd. (edgar:1679082) Operating Cash Flow: -224088000 USD Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -224088000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331.htm#1490626 Filing: 000167908221000017 The citation records this snapshot. The page link may show a newer release later.	USD 1.24 million Exact value Exact value: 1236000 USD 2018-04-01 – 2019-03-31: 1236000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Myovant Sciences Ltd. · 2019-03-31 Myovant Sciences Ltd. (edgar:1679082) Capital Expenditure: 1236000 USD Concept: fundies:CapitalExpenditure Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ACapitalExpenditure&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1236000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331.htm#1504238 Filing: 000167908221000017 The citation records this snapshot. The page link may show a newer release later.	−USD 225.32 million Calculation and evidence -224088000 − 1236000 USD Exact free cash flow: -225324000 USD 2018-04-01 – 2019-03-31: -224088000 USD · Inspect Operating Cash Flow · Source 2018-04-01 – 2019-03-31: 1236000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Myovant Sciences Ltd. · 2019-03-31 Myovant Sciences Ltd. (edgar:1679082) Free cash flow: -225324000 USD Concept: free-cash-flow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -224088000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331.htm#1490626 Filing: 000167908221000017 Input fundies:CapitalExpenditure: 1236000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331.htm#1504238 Filing: 000167908221000017 The citation records this snapshot. The page link may show a newer release later.
2020 2019-04-01 – 2020-03-31	−USD 288.99 million Exact value Exact value: -288989000 USD 2019-04-01 – 2020-03-31: -288989000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Myovant Sciences Ltd. · 2020-03-31 Myovant Sciences Ltd. (edgar:1679082) Net Income: -288989000 USD Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:NetIncome: -288989000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1461490 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	−USD 221.17 million Exact value Exact value: -221172000 USD 2019-04-01 – 2020-03-31: -221172000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Myovant Sciences Ltd. · 2020-03-31 Myovant Sciences Ltd. (edgar:1679082) Operating Cash Flow: -221172000 USD Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -221172000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1539687 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	USD 1.1 million Exact value Exact value: 1099000 USD 2019-04-01 – 2020-03-31: 1099000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Myovant Sciences Ltd. · 2020-03-31 Myovant Sciences Ltd. (edgar:1679082) Capital Expenditure: 1099000 USD Concept: fundies:CapitalExpenditure Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ACapitalExpenditure&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1099000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1553346 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	−USD 222.27 million Calculation and evidence -221172000 − 1099000 USD Exact free cash flow: -222271000 USD 2019-04-01 – 2020-03-31: -221172000 USD · Inspect Operating Cash Flow · Source 2019-04-01 – 2020-03-31: 1099000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Myovant Sciences Ltd. · 2020-03-31 Myovant Sciences Ltd. (edgar:1679082) Free cash flow: -222271000 USD Concept: free-cash-flow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -221172000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1539687 Filing: 000167908222000071 Input fundies:CapitalExpenditure: 1099000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1553346 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.
2021 2020-04-01 – 2021-03-31	−USD 255.13 million Exact value Exact value: -255134000 USD 2020-04-01 – 2021-03-31: -255134000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Myovant Sciences Ltd. · 2021-03-31 Myovant Sciences Ltd. (edgar:1679082) Net Income: -255134000 USD Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:NetIncome: -255134000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1460313 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	USD 370.63 million Exact value Exact value: 370628000 USD 2020-04-01 – 2021-03-31: 370628000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Myovant Sciences Ltd. · 2021-03-31 Myovant Sciences Ltd. (edgar:1679082) Operating Cash Flow: 370628000 USD Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 370628000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1538639 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	USD 1.77 million Exact value Exact value: 1773000 USD 2020-04-01 – 2021-03-31: 1773000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Myovant Sciences Ltd. · 2021-03-31 Myovant Sciences Ltd. (edgar:1679082) Capital Expenditure: 1773000 USD Concept: fundies:CapitalExpenditure Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ACapitalExpenditure&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1773000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1552357 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	USD 368.86 million Calculation and evidence 370628000 − 1773000 USD Exact free cash flow: 368855000 USD 2020-04-01 – 2021-03-31: 370628000 USD · Inspect Operating Cash Flow · Source 2020-04-01 – 2021-03-31: 1773000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Myovant Sciences Ltd. · 2021-03-31 Myovant Sciences Ltd. (edgar:1679082) Free cash flow: 368855000 USD Concept: free-cash-flow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 370628000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1538639 Filing: 000167908222000071 Input fundies:CapitalExpenditure: 1773000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1552357 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.
2022 2021-04-01 – 2022-03-31	−USD 205.98 million Exact value Exact value: -205981000 USD 2021-04-01 – 2022-03-31: -205981000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Net Income: -205981000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:NetIncome: -205981000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1459136 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	−USD 268.56 million Exact value Exact value: -268559000 USD 2021-04-01 – 2022-03-31: -268559000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Operating Cash Flow: -268559000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -268559000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1537588 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	USD 974,000 Exact value Exact value: 974000 USD 2021-04-01 – 2022-03-31: 974000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Capital Expenditure: 974000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082/explain?concept=fundies%3ACapitalExpenditure&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 974000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1551399 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.	−USD 269.53 million Calculation and evidence -268559000 − 974000 USD Exact free cash flow: -269533000 USD 2021-04-01 – 2022-03-31: -268559000 USD · Inspect Operating Cash Flow · Source 2021-04-01 – 2022-03-31: 974000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Myovant Sciences Ltd. · 2022-03-31 Myovant Sciences Ltd. (edgar:1679082) Free cash flow: -269533000 USD Concept: free-cash-flow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1679082?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -268559000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1537588 Filing: 000167908222000071 Input fundies:CapitalExpenditure: 974000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1679082/000167908222000071/myov-20220331.htm#1551399 Filing: 000167908222000071 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

100 filings · 1,684 latest values · 1,679 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001679082, 1679082, MYOV, edgar:1679082

Also known as Myovant Sciences Ltd.

Myovant Sciences Ltd.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2021-04-01 – 2022-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation